Table 1.
Clinical and Pathologic Characteristics of All 240 Primary Lung Adenocarcinoma Tumors Studied and Their Association With 4 Histologic Pattern Groups
| Histologic Pattern Group: No. of Patients (%)a | ||||||
|---|---|---|---|---|---|---|
| Characteristic | All Tumors, N = 240 | Group 1, N = 92 | Group 2, N = 34 | Group 3, N = 72 | Group 4, N = 42 | P |
| Age, yb | .00079 | |||||
| ≤66.8 | 118 | 53 (45) | 20 (17) | 21 (18) | 24 (20) | |
| >66.8 | 122 | 39 (32) | 14 (11) | 51 (42) | 18 (15) | |
| Sex | .09314 | |||||
| Women | 137 | 47 (34) | 16 (12) | 49 (36) | 25 (18) | |
| Men | 103 | 45 (44) | 18 (17) | 23 (22) | 17 (17) | |
| Smoking status | .00010 | |||||
| Current | 97 | 54 (56) | 13 (13) | 15 (15) | 15 (15) | |
| Former | 102 | 30 (29) | 15 (15) | 37 (36) | 20 (20) | |
| Never | 41 | 8 (20) | 6 (15) | 20 (49) | 7 (17) | |
| IASLC stagec | .01377 | |||||
| I | 167 | 54 (32) | 23 (14) | 60 (36) | 30 (18) | |
| II | 42 | 23 (55) | 8 (19) | 7 (17) | 4 (10) | |
| III or IV | 31 | 15 (48) | 3 (10) | 5 (16) | 8 (26) | |
| TNM staged | .00164 | |||||
| I | 173 | 55 (32) | 24 (14) | 63 (36) | 31 (18) | |
| II | 36 | 22 (61) | 7 (19) | 4 (11) | 3 (8) | |
| III or IV | 31 | 15 (48) | 3 (10) | 5 (16) | 8 (26) | |
| Adjuvant therapye | .27792 | |||||
| No | 163 | 57 (35) | 26 (16) | 53 (33) | 27 (17) | |
| Yes | 71 | 33 (47) | 7 (10) | 18 (25) | 13 (18) | |
| Necrosis | <.0001 | |||||
| No | 114 | 26 (23) | 19 (17) | 48 (42) | 21 (18) | |
| Yes | 126 | 66 (52) | 15 (12) | 24 (19) | 21 (17) | |
| Lymphovascular invasion | .1398 | |||||
| No | 200 | 74 (37) | 26 (13) | 66 (33) | 34 (17) | |
| Yes | 40 | 18 (45) | 8 (20) | 6 (15) | 8 (20) | |
Abbreviations: IASLC, International Association for the Study of Lung Cancer; TNM, tumor, lymph node, metastasis.
Histologic pattern groups were defined as follows: group 1, tumors with any solid pattern; group 2, any papillary pattern but no solid pattern; group 3, acinar and lepidic patterns but no solid or papillary patterns; and group 4, acinar pattern only.
The median age of the entire population is indicated.
See Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136:260–271.38
See Mountain CF. The international system for staging lung cancer. Semin Surg Oncol. 2000;18:106–115.37
Adjuvant treatment information was not available for 6 patients.